NCT03580382View on ClinicalTrials.gov

Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma

PHASE1/PHASE2TerminatedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

July 6, 2018

Primary Completion Date

September 26, 2018

Study Completion Date

September 26, 2018

Conditions
Melanoma
Interventions
DRUG

Trametinib daily Until PD

1.0 mg daily

DRUG

CDX-3379 (ERBB3 antibody)

15mg/kg IV Q3W

Trial Locations (2)

10016

New York University School of Medicine, New York

19107

Thomas Jefferson University, Philadelphia

Sponsors

Collaborators (1)

Celldex Therapeutics
All Listed Sponsors
collaborator

Celldex Therapeutics

INDUSTRY

lead

NYU Langone Health

OTHER

NCT03580382 - Study of CDX-3379, a Human Monoclonal Antibody Targeting ERBB3, in Combination With the MEK Inhibitor, Trametinib, in Patients With Advanced Stage NRAS Mutant and BRAF/NRAS Wildtype (WT) Melanoma | Biotech Hunter | Biotech Hunter